PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026British Journal of Dermatology0 citations

Chimeric antigen receptor T-cell therapy for relapsed/refractory primary cutaneous B-lymphoblastic lymphoma with rapid and durable systemic regression

View Full Paper
XGXinai GanYWYijun WuXSXu Sun

Key Points

  • To explore the effectiveness of CAR-T therapy in treating relapsed/refractory primary cutaneous B-LBL.
  • Case report of a 53-year-old woman with relapsed/refractory primary cutaneous B-LBL
  • Treatment with chimeric antigen receptor T-cell therapy after multiple previous treatments
  • Achieved rapid systemic regression of lymphoma after CAR-T therapy
  • Durable response noted, suggesting potential for long-term remission

Abstract

B-lymphoblastic lymphoma (B-LBL) is a rare, aggressive non-Hodgkin lymphoma. Primary cutaneous involvement is extremely uncommon, contributing to diagnostic delays, treatment challenges and poor prognosis. We report a 53-year-old woman with relapsed/refractory primary cutaneous B-LBL who, after multiple treatments, achieved rapid and durable systemic regression via chimeric antigen receptor T-cell (CAR-T) therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gan et al. (2025) studied this question.

synapsesocial.com/papers/698829520fc35cd7a8849897https://doi.org/10.1093/bjd/ljaf484
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia2014 · 5,472 citations
  2. 2Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: A series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma2013 · 64 citations
  3. 3CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome2020 · 25 citations
  4. 4Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia2021 · 192 citations
  5. 5Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine2022 · 152 citations